Having filed for bankruptcy in 2003, Biotransplant is no longer operational. Biotransplant was a development stage company engaged in discovering, developing and commercializes therapeutics, therapeutic devices and therapeutic regimens designed to suppress undesired immune responses and enhance the body's ability to accept donor cells, tissues and organs. The firm's pharmaceuticals and systems are designed to re-educate the body's immune system to accept foreign tissue, allowing safer, more enduring organ transplantation. The Company is also creating potentially valuable new treatments for other diseases such as blood cell cancers. Specifically, the Company's products under development include MEDI-507, the AlloMune System, and the XenoMune System. Initially focused on enhancing the safety and expanding access to organ transplants, the firm advanced development of a range of products with multiple indications, both alone and in partnership with leading pharmaceutical companies. Following decision to close, the Company exclusively licensed Siplizumab (MEDI-507), a monoclonal antibody product, to MedImmune, Inc. In October 2003, BioTransplant sold its Eligix HDM Cell Separation Systems to Miltenyi Biotec GmbH . The Company's assets also include its AlloMune System technologies, intended to treat a variety of hematologic malignancies and improve outcomes for solid organ transplants. BioTransplant also has a 33% interest in Immerge BioTherapeutics, AG, a joint venture with Novartis, to further develop both companies' individual technology bases in xenotransplantation and a less than 10% interest in Stem Cell Sciences, a life sciences company with operations in Australia and Scotland.
